Sight Diagnostics’ OLO Deployed in Israeli Hospital to Help Support Coronavirus Quarantine Measures
Sight and Sheba Tel Hashomer today announced their new collaboration aimed at mitigating the risk of contamination by COVID-19. Sight’s OLO blood analyser will provide rapid FBC (full blood count) results in a dedicated lab within Israel’s flagship government-run hospital, to process samples of infected patients who are being monitored and treated in a separate field hospital.
Prior to deploying OLO for coronavirus patient testing, Sight ran a two-month evaluation at the central lab of Sheba Tel Hashomer, one of the top 10 hospitals in the world, according to Newsweek, and one of the biggest in Israel. The successful results led to implementing OLO for FBC testing.
Currently, OLO is being used for routine testing of Sheba’s positive coronavirus patients. “OLO’s compact design makes it easy to set up quickly in a setting reserved for testing only contagious blood samples. Eliminating the risks of processing these samples alongside regular lab samples is uniquely advantageous in managing outbreaks of highly infectious diseases,” said Dr. Ram Doolman, Director of Sheba’s Laboratories Division and Automated Mega-Laboratory. “By setting up a quarantined lab that requires special protocols in handling samples from infected patients, we are taking the necessary steps to protect our staff who are on the frontlines, fighting the coronavirus epidemic.”
“Typically, monitoring a patient infected with a virus like COVID-19 would involve taking a blood sample from the infected individual with a needle, labeling vials of drawn blood, sending those vials to a lab outside of the quarantine zone, and receiving the results of the test an hour or more later,” said Yossi Pollak, CEO of Sight. “OLO gives health care providers the ability to use a self-contained cartridge to collect two drops of blood, from either a venous or finger prick sample, insert the cartridge into OLO, and receive FBC results in minutes. For health facilities in countries where OLO is available for point-of-care use, that tactical advantage could make a big difference in a field setting.”
OLO’s technology combines computer vision and AI to digitise each blood sample into more than 1,000 high resolution images. ”We are planning to further develop our technology to diagnose serious conditions, including complications that stem from a viral infection, that have a distinct visual signature in the blood sample,” said Yochay Eshel, VP of R&D at Sight. “We believe in the impact our technology could have on the management of infectious disease, and we are keen to do our part to help.”
Sight is committed to providing rapid and accurate blood tests to aid health professionals in diagnosing and treating patients around the world. By applying technological innovation to blood diagnostics, Sight hopes to improve the ways in which healthcare professionals tackle the challenging effects of infectious diseases.
CAUTIONARY STATEMENT: This press release is intended for distribution outside of the United States. OLO has the CE Mark registration from the European directive for performing FBC tests in point of care settings. In the United States, OLO is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point of care use.
About Sight Diagnostics
Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing. Sight’s technology, developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s latest blood analyser, OLO, performs a Full Blood Count, the most commonly ordered blood test, in minutes. It’s compact: designed to be used in a variety of settings. OLO creates a digital version of a blood sample by capturing more than 1,000 highly detailed images from just two drops of blood obtained from a finger prick or venous sample. These images are then interpreted by proprietary and fully automated AI algorithms. Sight’s first product, Parasight, has been used to detect malaria in almost 1 million tests across 24 countries. The company has rapidly growing offices in the UK, the US and Israel. Learn more at sightdx.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005027/en/
Contact information
Emma Baron
Senior Account Executive
VSC for Sight Diagnostics
sight@vsc.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 19:42:00 EET | Press release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 18:00:00 EET | Press release
CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on improved vulnerability and threat management visibility and automated and predictive attack detection capabilities.” It also notes, “By addressing these evolving identity types within a unified framework, CyberArk enh
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 15:30:00 EET | Press release
The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York—its people, its environment, and its youth. Ant International’s commitment to community empowerment, sustai
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 15:00:00 EET | Press release
Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too few carriers of the variant exist to draw statistically meaningful conclusions. As a result, even the most advanced models trained on observational datas
Cyviz Awarded Two Classified NATO Defense Contracts19.12.2025 09:00:00 EET | Press release
Norwegian technology and platform company Cyviz AS has been awarded two classified defense contracts by major European NATO-partner nations to deliver a fully mobile, containerised Command & Control (C2) capability, strengthening Europe’s operational readiness in high-threat and expeditionary environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218625485/en/ Image from a previous military exercise where Cyviz demonstrated a mobile command center solution. The contracts cover the design, integration, and delivery of secure, deployable operations centres engineered to NATO security standards, enabling military and security forces to establish full theatre-class command capability wherever operations require. Due to the sensitive nature of the missions, contract value and customer identities remain undisclosed. From Demonstrated Readiness to Operational Deployment The awards follow growing interest among European def
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom